Transitioning from Haloperidol to Quetiapine for Agitated Behaviors

Rationale for Switching

• The National Comprehensive Cancer Network (NCCN) guidelines recommend quetiapine fumarate 50-100 mg PO twice daily as an alternative agent for delirium and agitation management, supporting the proposed starting dose 1, 2, 3

Recommended Transition Protocol

• Initiate quetiapine 50 mg twice daily and convert haloperidol to PRN dosing: 0.5-1 mg every 2 hours as needed for breakthrough agitation 1, 2, 3, 4
• Continue quetiapine 50 mg twice daily and assess response, reducing haloperidol PRN availability or discontinuing entirely if agitation is well-controlled 1, 2, 5

Critical Monitoring Parameters

• Evaluate agitation control daily using objective measures to determine if haloperidol PRN is needed or if quetiapine dose adjustment is required 1, 2
• Assess for extrapyramidal symptoms (EPS) from haloperidol, including shuffling gait, as these should improve with the switch to quetiapine 5

Common Pitfalls to Avoid

• Do not abruptly discontinue haloperidol without overlap, as this may cause symptom rebound during the 2-3 day period before quetiapine reaches steady state 5
• Do not assume all agitation is psychiatric—ensure you've ruled out or addressed reversible causes like infection, metabolic derangements, hypoxia, urinary retention, or constipation before attributing symptoms solely to the underlying psychiatric condition 1, 2, 3, 4

Dose Titration Strategy if Needed

• If 50 mg twice daily quetiapine is insufficient after 3-5 days, increase to 100 mg twice daily as this is within the guideline-recommended range for agitation 1, 2, 3
• Maximum recommended dose for agitation is typically 200 mg daily (100 mg twice daily), though higher doses may be used under specialist supervision 1, 2, 3